Clinical Trial Update: GALLANT 22 Tesaglitazar vs. Placebo [Phase 3]

View source ↗

Summary

Phase 3 trial of Tesaglitazar versus placebo for type 2 diabetes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tesaglitazar (tesaglitazar)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes | Phase 3 | Status: TERMINATED